📣 VC round data is live. Check it out!

Curaleaf Valuation Multiples

Discover Curaleaf's revenue and EBITDA valuation multiples and M&A history, alongside public comparables like Green Thumb Industries, Trulieve Cannabis, Cronos Group, Glass House Brands and more.

Curaleaf Overview

About Curaleaf

Curaleaf is headquartered in Wakefield, Massachusetts, and cultivates and sells medicinal and recreational cannabis in the US. The company has operations in 17 states. Its brands include Curaleaf, Select, and Grassroots. The company has made acquisitions that give it exposure to the growing European market, a unique feature among US multistate operators.


Founded

2014

HQ

United States

Employees

5.5K

Financials (LTM)

Revenue: $1B
EBITDA: $274M

EV

$4B

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Curaleaf Financials

Curaleaf reported last 12-month revenue of $1B and EBITDA of $274M.

In the same LTM period, Curaleaf generated $638M in gross profit, $274M in EBITDA, and had net loss of ($175M).

Revenue (LTM)


Curaleaf P&L

In the most recent fiscal year, Curaleaf reported revenue of - and net income of -.

See analyst estimates for Curaleaf
LTM2025202620272028
Revenue$1B$1B
Gross Profit$638M$627M
Gross Margin49%49%
EBITDA$274M$275M
EBITDA Margin21%22%
EBIT Margin2%2%
Net Profit($175M)($231M)
Net Margin(13%)(18%)

Financial data powered by Morningstar, Inc.

Curaleaf Stock Performance

Curaleaf has current market cap of $3B, and enterprise value of $4B.

Market Cap Evolution


Curaleaf's stock price is $3.94.

Curaleaf share price increased by 368.8% in the last year.

See more trading valuation data for Curaleaf
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$4B$3B0.0%-82.9%368.8%-

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Curaleaf Valuation Multiples

Curaleaf trades at 3.0x EV/Revenue multiple, and 14.0x EV/EBITDA.

See NTM and 2027E valuation multiples for Curaleaf

EV / Revenue (LTM)


Curaleaf Financial Valuation Multiples

As of June 2, 2026, Curaleaf has market cap of $3B and EV of $4B.

Curaleaf has a P/E ratio of (17.9x).

LTM2025202620272028
EV/Revenue3.0x3.0x
EV/EBITDA14.0x14.0x
EV/EBIT166.5x193.7x
EV/Gross Profit6.0x6.1x
P/E(17.9x)(13.5x)
EV/FCF64.3x53.7x

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Curaleaf Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Curaleaf Margins & Growth Rates

See estimated margins and future growth rates for Curaleaf

Curaleaf Margins

20252026202720282029
Gross Margin49%49%
EBITDA Margin22%20%
EBIT Margin2%2%
Net Margin(18%)(7%)
FCF Margin6%3%

Curaleaf Growth Rates

25/2626/2727/2828/29
Revenue Growth6%
Gross Profit Growth4%
EBITDA Growth(1%)
EBIT Growth39%
Net Profit Growth(58%)
FCF Growth(39%)

Data powered by FactSet, Inc. and Morningstar, Inc.

Curaleaf Operational KPIs

Curaleaf's Rule of 40 is 26% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Curaleaf's Rule of X is 34% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Curaleaf
LTMLast FY2025202620272028
Rule of 4028%26%-
Bessemer Rule of X38%34%-
G&A Expenses to Revenue34%-34%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Curaleaf Competitors

Curaleaf competitors include Green Thumb Industries, Trulieve Cannabis, Cronos Group, Glass House Brands, Tilray Brands, Vireo Growth, Canopy Growth and Verano Holdings.

Most Curaleaf public comparables operate across Cannabis, CannaTech and ViceTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Green Thumb Industries-1.6x-5.5x
Trulieve Cannabis-1.6x-4.5x
Cronos Group1.7x1.5x208.2x28.1x
Glass House Brands-4.0x-32.0x
Tilray Brands0.9x0.9x13.7x12.0x
Vireo Growth-1.8x-7.0x

This data is available for Pro users. Sign up to see all Curaleaf competitors and their valuation data.

Start Free Trial

Acquisitions by Curaleaf

Curaleaf has acquired 13 companies to date.

Last acquisition by Curaleaf was on March 19th 2024. Curaleaf acquired Northern Green Canada for $16M (EV/Revenue multiple available to Pro users).

See M&A valuation multiples

Latest Acquisitions by Curaleaf

Northern Green Canada
Can4Med
Deseret Wellness
Four 20 Pharma
Description
Northern Green Canada is a Val-d'Or-based licensed producer of recreational and medicinal cannabis products in Quebec, Canada. It cultivates strains like Northern Lights and distributes oils, edibles, and dried flower through provincial retail networks. The company operates a 25,000-square-foot facility compliant with Health Canada regulations.
Can4Med is a Warsaw-based licensed pharmaceutical wholesaler authorized for trading medicinal products, narcotics in groups I-N, and dried prescription drugs across Poland. The company supplies hospitals, pharmacies, and healthcare providers with a range of pharmaceuticals while complying with strict regulatory standards for storage and distribution.
Deseret Wellness is a cannabis therapy provider with cultivation, manufacturing, and dispensary operations in regulated medical markets. The team manages facilities in multiple US states, producing oils, edibles, and topicals from strains grown indoors. Deseret emphasizes compliance with state health departments for patient access programs.
Four 20 Pharma is a Mönchengladbach-based producer and distributor of medical cannabis products under full EU-GMP and GDP certification. It manufactures flower, oils, and extracts from strains like Bedrocan and Pedanios, supplying pharmacies across Germany and 12 European countries. The company operates a 2,000 square meter facility with cultivation greenhouses yielding 1,000 kg annually. Four 20 Pharma partners with Dutch growers for standardized cultivars since 2018.
HQ CountryUnited KingdomPolandUnited StatesGermany
HQ City
Toronto
Wroclaw
Provo, UT
Paderborn
Deal Date19 Mar 20246 Feb 202429 Mar 20239 Aug 2022
Valuation$16Mundisclosed$20M$36M
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Curaleaf acquisitions and their M&A valuation multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Curaleaf

When was Curaleaf founded?Curaleaf was founded in 2014.
Where is Curaleaf headquartered?Curaleaf is headquartered in United States.
How many employees does Curaleaf have?As of today, Curaleaf has over 5K employees.
Who is the CEO of Curaleaf?Curaleaf's CEO is Boris Jordan.
Is Curaleaf publicly listed?Yes, Curaleaf is a public company listed on OTC Pink Sheets.
What is the stock symbol of Curaleaf?Curaleaf trades under CURLF ticker.
When did Curaleaf go public?Curaleaf went public in 2018.
Who are competitors of Curaleaf?Curaleaf main competitors include Green Thumb Industries, Trulieve Cannabis, Cronos Group, Glass House Brands, Tilray Brands, Vireo Growth, Canopy Growth, Verano Holdings.
What is the current market cap of Curaleaf?Curaleaf's current market cap is $3B.
What is the current revenue of Curaleaf?Curaleaf's last 12 months revenue is $1B.
What is the current revenue growth of Curaleaf?Curaleaf revenue growth (NTM/LTM) is 7%.
What is the current EV/Revenue multiple of Curaleaf?Current revenue multiple of Curaleaf is 3.0x.
What is the current EBITDA of Curaleaf?Curaleaf's last 12 months EBITDA is $274M.
What is Curaleaf's EBITDA margin?Curaleaf's last 12 months EBITDA margin is 21%.
What is the current EV/EBITDA multiple of Curaleaf?Current EBITDA multiple of Curaleaf is 14.0x.
What is the current FCF of Curaleaf?Curaleaf's last 12 months FCF is $60M.
What is Curaleaf's FCF margin?Curaleaf's last 12 months FCF margin is 5%.
What is the current EV/FCF multiple of Curaleaf?Current FCF multiple of Curaleaf is 64.3x.
How many companies Curaleaf has acquired to date?As of June 2026, Curaleaf has acquired 13 companies.
What was the largest acquisition by Curaleaf?$949M acquisition of Cura Partners on 1st May 2019 was the largest M&A Curaleaf has done to date.
What companies Curaleaf acquired?Curaleaf acquired Cura Partners, Grassroots Cannabis, Tryke, EMMAC Life Sciences, Bloom Dispensary, Acres Cannabis, Los Sueños Farms, Four 20 Pharma, Deseret Wellness, Northern Green Canada, and 3 other companies.
In how many companies Curaleaf has invested to date?Curaleaf hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Curaleaf

Lists including Curaleaf

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial